215 related articles for article (PubMed ID: 7038899)
1. [Introduction to clinical pharmacodynamics and pharmacokinetics of cardiac glycosides].
Kudrin AN; Namakanov BA; Davydova ON
Sov Med; 1981; (11):70-4. PubMed ID: 7038899
[No Abstract] [Full Text] [Related]
2. [Pharmacology of cardiotonic glycosides].
Berdeaux A
Rev Prat; 1986 Oct; 36(43):2499-505. PubMed ID: 3787145
[No Abstract] [Full Text] [Related]
3. Current drug therapy: cardiac glycosides.
Am J Hosp Pharm; 1978 Dec; 35(12):1495-507. PubMed ID: 362913
[TBL] [Abstract][Full Text] [Related]
4. [Cardiac effects, relative enteral effectiveness and rate of inactivation of the cardiac glycoside meproscillarin].
Raschack M; Haas H; Neugebauer G; Sipos J
Arzneimittelforschung; 1978; 28(3a):495-502. PubMed ID: 580578
[No Abstract] [Full Text] [Related]
5. [Clinically relevant drug interactions with cardiac glycosides].
Bodem G
Fortschr Med; 1982 Oct; 100(38):1739-42. PubMed ID: 7141372
[No Abstract] [Full Text] [Related]
6. [Therapeutic equivalence and inequivalence of chemically identical substances using cardiac glycosides for an example (author's transpl)].
Rietbrock N
Arzneimittelforschung; 1976; 26(1A):135-46. PubMed ID: 947193
[TBL] [Abstract][Full Text] [Related]
7. [Modifying factors in carciac glycoside therapy].
Krebs R
Med Klin; 1976 Oct; 71(42):1759-70. PubMed ID: 790134
[No Abstract] [Full Text] [Related]
8. [Clinical pharmacology of cardiac glycosides].
Haustein KO
Pol Tyg Lek; 1978 May; 33(20):817-20. PubMed ID: 673918
[No Abstract] [Full Text] [Related]
9. [Pharmacokinetics of cardiac glycosides and clinical consequences].
Rietbrock N; Kuhlmann J; Vöhringer HF
Fortschr Med; 1977 Apr; 95(14):909-15, 951-4. PubMed ID: 856698
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of meproscillarin rates of inactivation and persistence, bioavailability and maintenance dose].
Herken H; Brandes J
Arzneimittelforschung; 1978; 28(3a):557-60. PubMed ID: 580590
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pharmacology of nonsteroidal anti-inflammatory agents. I: Pharmacokinetics].
Reinicke C
Z Arztl Fortbild (Jena); 1985; 79(8):321-6. PubMed ID: 3874491
[No Abstract] [Full Text] [Related]
12. [Binding of cardiac glycosides by the erythrocytes of patients].
Bakaev VV
Farmakol Toksikol; 1986; 49(5):25-7. PubMed ID: 3770168
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of chronic cardiac insufficiency with cardiac glycosides].
Bonelli J
Wien Med Wochenschr; 1982 Oct; 132(19):442-9. PubMed ID: 7179995
[No Abstract] [Full Text] [Related]
14. [Indications, contra-indications and dosage of cardiac glycosides controlled by plasma levels in the aged].
Hötter GJ
Z Gerontol; 1987; 20(1):8-12. PubMed ID: 3577317
[TBL] [Abstract][Full Text] [Related]
15. [Cardiac glycosides: their pharmacology and clinical pharmacology].
Greeff K
Med Monatsschr Pharm; 1984 Feb; 7(2):37-49. PubMed ID: 6321928
[No Abstract] [Full Text] [Related]
16. [Treatment of congestive heart failure with cardiac glycosides. I. New theses in the principles of treatment].
Tomov I
Vutr Boles; 1980; 19(6):7-14. PubMed ID: 7210653
[No Abstract] [Full Text] [Related]
17. Drug pharmacokinetics in thyroid dysfunction.
Rodighiero V
Minerva Endocrinol; 1985; 10(2):97-113. PubMed ID: 2415808
[No Abstract] [Full Text] [Related]
18. [Pharmacodynamics, pharmacokinetics and side effects of cardiac glycosides].
Sivkov II; Kukes VG; Ibadova DN; Shokhor VIa; Otdelenov AV
Vestn Akad Med Nauk SSSR; 1987; (9):83-7. PubMed ID: 3673236
[No Abstract] [Full Text] [Related]
19. [Cardiac glycosides--clinically relevant interactions].
Kuhlmann J
Med Monatsschr Pharm; 1982 Mar; 5(3):65-79. PubMed ID: 7040928
[No Abstract] [Full Text] [Related]
20. [Benzodiazepines. Factors altering pharmacokinetic parameters and drug interactions].
Singlas E
Encephale; 1983; 9(4 Suppl 2):67B-73B. PubMed ID: 6144532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
